Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management

Abstract Obesity continues to be a significant global health challenge, affecting over 800 million individuals worldwide. Traditional management strategies, including dietary, exercise, and behavioral interventions, often result in insufficient and unsustainable weight loss. Lifestyle modification remains the cornerstone of obesity management, providing the foundation for other strategies. While options such as bariatric surgery remain an effective intervention for severe obesity, it is associated with its own set of risks and is typically reserved for patients who have not achieved the desired results with pharmacotherapy and lifestyle interventions. Incretin hormone agonists represent a significant advancement in the pharmacotherapy of obesity, offering substantial weight reduction and cardiometabolic benefits. Agents like liraglutide, semaglutide, and tirzepatide supported by key clinical trials such as Satiety and Clinical Adipose Liraglutide Evidence (SCALE), Semaglutide Treatment Effect in People with Obesity (STEP) program trials, and Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT‐1) have demonstrated remarkable efficacy in promoting weight loss and improving metabolic outcomes. Additionally, novel therapies, including dual and triple incretin agonists, are under investigation and hold the potential for further advancements in obesity treatment. These novel therapies can be categorized by their mechanisms of action and route of administration into oral glucagon‐like peptide‐1 (GLP‐1) receptor agonists, triple agonists (targeting GLP‐1, glucose‐dependent insulinotropic polypeptide [GIP], and glucagon receptors), and glucagon receptor‐GLP‐1 receptor co‐agonists. Other innovative approaches include oral GIP‐GLP‐1 receptor co‐agonists, and the combination of long‐acting amylin receptor agonists with GLP‐1 receptor agonists. The ongoing development of incretin‐based therapies and the expanding availability of currently available agents are expected to enhance clinical outcomes further and reduce the burden of obesity‐related health complications. This review aims to discuss the mechanisms and efficacy of current and emerging incretin hormone agonists for obesity management.